AllSight
Companies · BHVN · Pharmaceutical Preparations

Biohaven Ltd. (BHVN)

Biohaven Ltd. (BHVN) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Biohaven Ltd. (BHVN) stock — financials & valuation

Key numbers for Biohaven Ltd. (BHVN): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 28/100 — a percentile rank of Biohaven Ltd.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$2.0B
EV / EBITDA-3.6×
Return on equity-4801.5%
ROIC-1688.9%
Debt / equity21.2×
Dividend yield0.0%

Is Biohaven Ltd. overvalued? P/B looks fair vs its 5-year range.

Independent of the events above — derived from Biohaven Ltd.’s own financial statements and shown as context, never as advice.

Sep 9, 2026Partial clinical hold
Biohaven’s BHV-7000 hit with partial FDA hold, but pivotal data timeline survives
Aug 26, 2026$400M platform license
Biohaven lands $400M Kv7 deal, but RISE3 data still decides opakalim’s value
Aug 10, 2026
Clinical pipeline advanced, but quarterly loss narrowly missed expectations
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact